MIRM NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Mirum Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 106.0 USD
-6.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 69.8% of its 52-week range. The latest completed week returned -6.3%, after a -15.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 54 out of 100
Latest Close 106.0 USD 31 Jul 2026
1W Return -6.3% latest completed week
4W Return -15.6% short-term follow-through
12W Return -1.1% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 58-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 6 reversal markers appear in the recent smart-money tape.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.3% Latest completed week; four-week move -15.6%. Indicator stack 100/56 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 56.76% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 46/100 conviction; expected move 10.2%. News sentiment 51/100 60 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 69.8% of its 52-week range. The latest completed week returned -6.3%, after a -15.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8812-week average 0.79

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.88Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers66 reversal markers

No recent accumulation markers. 6 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -15.6% over four weeks, -1.1% over 12 weeks, and 103.7% over one year. The current trend has remained active for 58 consecutive weeks.

Performance by holding period

1W-6.3%
4W-15.6%
12W-1.1%
26W2.6%
52W103.7%
Active trend streak58 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.49Latest activity-pressure read.
Pressure change-39.7%Four-week change in activity pressure.
Leadership10.27Latest relative-leadership reading.
RS change-67.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength53/100Blend of value, momentum, and quality. Underlying universe rank 48; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality68/100Profitability and accounting quality. Underlying universe rank 33; rank 1 is best.
Momentum96/100Medium-term price momentum. Underlying universe rank 5; rank 1 is best.
Growth86/100Revenue and earnings growth. Underlying universe rank 15; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
12.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-2.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
81.4%
Gross profit retained from each unit of revenue.
Operating margin
-138.0%
Operating profit retained from revenue.
Free-cash-flow margin
-29.7%
Free cash flow generated from revenue.
Return on invested capital
-244.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
50.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-1295.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

MIRM shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.24, expected move of 10.2%, and Sharemaestro trend signal active.

Conviction46/100
Expected move10.2%
Put/call volume0.24
Pressure66
Speculation8
Volatility77
Trend agreement33
Open options detail
Insider activity9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 60 relevant articles.

13 positive · 38 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move10.2%Nearest-chain priced movement where available.
52-week drawdown-18.5%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+15.5%Week of 26 Jun.
Worst week-12.2%Week of 27 Feb.
Latest week-6.3%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains6
Flat weeks0
Modest losses6
Sharp losses7
Recent vol7.0%13-week weekly-return volatility.
Base vol6.5%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis71/100

Latest 12-week confirmation: trend 12/12, activity pressure 6/12, relative leadership 12/12.

Activity pressure 0.88; 6 reversal markers Next-Week ExpectancyPositive 56.76%

Next-week expectancy is positive with a 56.76% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 58; Small Cap Core rank 88 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

MIRM shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.24, expected move of 10.2%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 10.2% Sentiment51/100

Weighted news tone is neutral across 60 relevant articles.

Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline Insiders9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026106.0 USD-6.3%100.8 USD54.14 USD0.4910.272.7MOn
24 Jul 2026113.0 USD-4.9%99.88 USD53.63 USD0.8519.263.3MOn
17 Jul 2026118.9 USD-2.7%98.75 USD53.07 USD1.1624.682.5MOn
10 Jul 2026122.1 USD-2.8%97.38 USD52.47 USD1.1324.143.6MOn
3 Jul 2026125.6 USD1.5%95.47 USD51.86 USD0.8231.333.7MOn
26 Jun 2026123.8 USD15.5%93.57 USD51.22 USD0.2932.168.6MOn
19 Jun 2026107.1 USD7.8%91.88 USD50.59 USD-0.1910.555.2MOn
12 Jun 202699.34 USD6.3%90.68 USD50.08 USD-0.446.022.9MOn
5 Jun 202693.48 USD-7.9%89.75 USD49.62 USD-0.332.723.2MOn
29 May 2026101.5 USD2.9%88.90 USD49.20 USD-0.037.233.3MOn
22 May 202698.62 USD-3.5%87.94 USD48.72 USD-0.118.034.3MOn
15 May 2026102.2 USD-4.6%86.98 USD48.26 USD-0.2314.1710.4MOn
8 May 2026107.2 USD11.0%86.03 USD47.77 USD-0.4420.408.0MOn
1 May 202696.53 USD5.5%84.88 USD47.25 USD-0.6715.483.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.